Cargando…

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis

Detalles Bibliográficos
Autores principales:	Dattola, Annunziata, Zangrilli, Arianna, Bianchi, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648422/ https://www.ncbi.nlm.nih.gov/pubmed/35024224 http://dx.doi.org/10.5826/dpc.1104a100

Ejemplares similares

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

IgA Staining Patterns Differentiate Between IgA Nephropathy and IgA-Dominant Infection-Associated Glomerulonephritis
por: Brodsky, Sergey V., et al.
Publicado: (2020)

Risankizumab for psoriasis
Publicado: (2020)

Serum Levels of LL-37 and Inflammatory Cytokines in Plaque and Guttate Psoriasis
por: Hwang, Young Ji, et al.
Publicado: (2014)

Anti-Programmed Cell Death-1-Induced Plaque and Guttate Psoriasis
por: Yamamoto, Toshiyuki
Publicado: (2018)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
por: Jung, Chang-Jin, et al.
Publicado: (2021)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Guttate psoriasis secondary to COVID-19
por: Gananandan, Kohilan, et al.
Publicado: (2020)

Tozinameran: Guttate psoriasis: case report
Publicado: (2022)

Tozinameran: Guttate psoriasis: case report
Publicado: (2022)

Childhood guttate psoriasis: an updated review
por: Leung, Alexander KC, et al.
Publicado: (2023)

Tissue and Serum Inflammatory Cytokine Levels in Korean Psoriasis Patients: A Comparison between Plaque and Guttate Psoriasis
por: Roh, Nam Kyung, et al.
Publicado: (2015)

Comparison between guttate and plaque psoriasis in terms of serum inflammatory cytokines and antimicrobial peptides
por: Liu, Xiao-Yang, et al.
Publicado: (2020)

Microbiota differences of skin and pharyngeal microbiota between patients with plaque and guttate psoriasis in China
por: Hu, Jingjin, et al.
Publicado: (2022)

Metabolic Syndrome in IgA Glomerulonephritis
por: Kaartinen, Kati, et al.
Publicado: (2014)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

IgA dominant poststaphylococcal glomerulonephritis: Complete recovery with steroid therapy
por: Eswarappa, M., et al.
Publicado: (2014)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

A Case of Lichen Planus Masquerading as Guttate Psoriasis
por: Muneem, Abraar, et al.
Publicado: (2020)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Histone Deacetylase 1 and Sirtuin 1 Expression in Psoriatic Skin: A Comparison between Guttate and Plaque Psoriasis
por: Hwang, Young-Ji, et al.
Publicado: (2020)

First presentation of guttate psoriasis triggered by acute tonsillitis
por: Koufakis, Theocharis, et al.
Publicado: (2014)

New‐onset guttate psoriasis secondary to COVID‐19
por: Rouai, Meriem, et al.
Publicado: (2021)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Is there a link between guttate psoriasis and SARS-CoV-2? A series of three cases()
por: Brazão, Cláudia, et al.
Publicado: (2022)

Comparison of Th1 and Th17 Inflammatory Cytokine Profiles Between Chronic Plaque and Acute Guttate Psoriasis
por: Ju, Hyun Jeong, et al.
Publicado: (2022)

Staphylococcus aureus Infection-Related Glomerulonephritis with Dominant IgA Deposition
por: Takayasu, Mamiko, et al.
Publicado: (2022)

Clinicopathologic Features of IgA-Dominant Postinfectious Glomerulonephritis
por: Koo, Tai Yeon, et al.
Publicado: (2012)

IgA nephropathy to proliferative glomerulonephritis with monoclonal IgAκ deposits: a pattern switch
por: Li, Jin-pu, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fqnei667tbpe59dihd9ddrjacc